Correlation Between Eterna Therapeutics and Novavax

Can any of the company-specific risk be diversified away by investing in both Eterna Therapeutics and Novavax at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eterna Therapeutics and Novavax into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eterna Therapeutics and Novavax, you can compare the effects of market volatilities on Eterna Therapeutics and Novavax and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eterna Therapeutics with a short position of Novavax. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eterna Therapeutics and Novavax.

Diversification Opportunities for Eterna Therapeutics and Novavax

0.63

Correlation Coefficient

Eterna Therapeutics  Novavax

Poor diversification

The 3 months correlation between Eterna and Novavax is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Eterna Therapeutics and Novavax in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novavax and Eterna Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eterna Therapeutics are associated (or correlated) with Novavax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novavax has no effect on the direction of Eterna Therapeutics i.e., Eterna Therapeutics and Novavax go up and down completely randomly.

Pair Corralation between Eterna Therapeutics and Novavax

Given the investment horizon of 90 days Eterna Therapeutics is expected to under-perform the Novavax. In addition to that, Eterna Therapeutics is 1.5 times more volatile than Novavax. It trades about -0.28 of its total potential returns per unit of risk. Novavax is currently generating about -0.08 per unit of volatility. If you would invest  1,293  in Novavax on September 17, 2024 and sell it today you would lose (382.00) from holding Novavax or give up 29.54% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Eterna Therapeutics  vs.  Novavax

Eterna Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Novavax

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novavax has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Eterna Therapeutics and Novavax

The main advantage of trading using opposite Eterna Therapeutics and Novavax positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eterna Therapeutics position performs unexpectedly, Novavax can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novavax will offset losses from the drop in Novavax's long position.

The idea behind Eterna Therapeutics and Novavax pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.